WEKO3
アイテム
{"_buckets": {"deposit": "8f765f51-2746-4f41-b7eb-13d5ca55743c"}, "_deposit": {"created_by": 2, "id": "17035", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "17035"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00017035", "sets": ["30"]}, "author_link": ["66175", "66172", "66174", "66168", "66178", "66169", "66170", "66177", "66176", "66173", "66171", "66167"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2008-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "12", "bibliographicPageEnd": "2244", "bibliographicPageStart": "2237", "bibliographicVolumeNumber": "31", "bibliographic_titles": [{"bibliographic_title": "Biological \u0026 Pharmaceutical Bulletin"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "To assess whether azelnidipine (AZN) exerts renoprotective effects, 20-week-old adult male stroke-prone spontaneously hypertensive rats (SHRsp) were treated with AZN 10 mg/kg/d (n=6), olmesartan (OLM) 3 mg/kg/d (n=4), hydralazine (HYD) 20 mg/kg/d (n=3), or water (control; n=5). Each test agent was administered by oral gavage for 12 weeks. Systolic blood pressure (SBP) was measured every 2 weeks and urinary protein excretion (UproV) every 3 weeks. At the age of 32 weeks, the rats were sacrificed and blood and kidneys collected for biochemical, histological, and immunohistochemical studies. All drug treatments significantly (p\u003c0.05) reduced SBP, UproV, and blood biochemical parameters such as creatinine, total cholesterol, and blood urea nitrogen. Masson trichrome staining and immunohistochemical staining revealed significant (p\u003c0.05) reductions of interstitial fibrosis, collagen type III, nicotinamide-adenine dinucleotide/nicotinamide-adenine dinucleotide phosphate oxidase, and p22phox and p47phox components expression in the AZN- and OLM-treated groups in comparison with rats treated with HYD and control animals. ED1, 4-hydroxy-2-nonenal (4-HNE), and heat shock protein (HSP)-47 expression was also reduced in the AZN- and OLM-treated groups versus in HYD and control animals. These results indicate that not only OLM but also AZN exerts renoprotective effects through inhibition of macrophage infiltration and antioxidant activity in SHRsp model of renal injury.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Biological \u0026 Pharmaceutical Bulletin, 31(12), pp.2237-2244; 2008", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Pharmaceutical Society of Japan"}]}, "item_2_relation_11": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "19043206", "subitem_relation_type_select": "PMID"}}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1248/bpb.31.2237", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "(c) 2008 Pharmaceutical Society of Japan."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "09186158", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1347-5215", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kurashige, Tomomi"}], "nameIdentifiers": [{"nameIdentifier": "66167", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Abe, Katsushige"}], "nameIdentifiers": [{"nameIdentifier": "66168", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Furusu, Akira"}], "nameIdentifiers": [{"nameIdentifier": "66169", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyazaki, Masanobu"}], "nameIdentifiers": [{"nameIdentifier": "66170", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Obata, Yoko"}], "nameIdentifiers": [{"nameIdentifier": "66171", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Xia, Zihyin"}], "nameIdentifiers": [{"nameIdentifier": "66172", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakazawa, Masayuki"}], "nameIdentifiers": [{"nameIdentifier": "66173", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakazawa, Yuka"}], "nameIdentifiers": [{"nameIdentifier": "66174", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Funakoshi, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "66175", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Harada, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "66176", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Koji, Takehiko"}], "nameIdentifiers": [{"nameIdentifier": "66177", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kohno, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "66178", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-23"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "BPB31_12_2237.pdf", "filesize": [{"value": "8.8 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 8800000.0, "url": {"label": "BPB31_12_2237.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/17035/files/BPB31_12_2237.pdf"}, "version_id": "29db3e61-c92a-4045-b6b5-224e0f41a2cb"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Antioxidant", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Azelnidipine", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Calcium channel blocker", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Hypertension", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Renoprotective effect", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Renoprotective Effect of Azelnidipine in Rats", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Renoprotective Effect of Azelnidipine in Rats"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/20860", "pubdate": {"attribute_name": "公開日", "attribute_value": "2009-01-26"}, "publish_date": "2009-01-26", "publish_status": "0", "recid": "17035", "relation": {}, "relation_version_is_last": true, "title": ["Renoprotective Effect of Azelnidipine in Rats"], "weko_shared_id": -1}
Renoprotective Effect of Azelnidipine in Rats
http://hdl.handle.net/10069/20860
http://hdl.handle.net/10069/208604fc971c7-b39d-4ed5-a9a1-ee78d0969c2e
名前 / ファイル | ライセンス | アクション |
---|---|---|
BPB31_12_2237.pdf (8.8 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2009-01-26 | |||||
タイトル | ||||||
タイトル | Renoprotective Effect of Azelnidipine in Rats | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Antioxidant | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Azelnidipine | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Calcium channel blocker | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Hypertension | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Renoprotective effect | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Kurashige, Tomomi
× Kurashige, Tomomi× Abe, Katsushige× Furusu, Akira× Miyazaki, Masanobu× Obata, Yoko× Xia, Zihyin× Nakazawa, Masayuki× Nakazawa, Yuka× Funakoshi, Satoshi× Harada, Takashi× Koji, Takehiko× Kohno, Shigeru |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | To assess whether azelnidipine (AZN) exerts renoprotective effects, 20-week-old adult male stroke-prone spontaneously hypertensive rats (SHRsp) were treated with AZN 10 mg/kg/d (n=6), olmesartan (OLM) 3 mg/kg/d (n=4), hydralazine (HYD) 20 mg/kg/d (n=3), or water (control; n=5). Each test agent was administered by oral gavage for 12 weeks. Systolic blood pressure (SBP) was measured every 2 weeks and urinary protein excretion (UproV) every 3 weeks. At the age of 32 weeks, the rats were sacrificed and blood and kidneys collected for biochemical, histological, and immunohistochemical studies. All drug treatments significantly (p<0.05) reduced SBP, UproV, and blood biochemical parameters such as creatinine, total cholesterol, and blood urea nitrogen. Masson trichrome staining and immunohistochemical staining revealed significant (p<0.05) reductions of interstitial fibrosis, collagen type III, nicotinamide-adenine dinucleotide/nicotinamide-adenine dinucleotide phosphate oxidase, and p22phox and p47phox components expression in the AZN- and OLM-treated groups in comparison with rats treated with HYD and control animals. ED1, 4-hydroxy-2-nonenal (4-HNE), and heat shock protein (HSP)-47 expression was also reduced in the AZN- and OLM-treated groups versus in HYD and control animals. These results indicate that not only OLM but also AZN exerts renoprotective effects through inhibition of macrophage infiltration and antioxidant activity in SHRsp model of renal injury. | |||||
書誌情報 |
Biological & Pharmaceutical Bulletin 巻 31, 号 12, p. 2237-2244, 発行日 2008-12 |
|||||
出版者 | ||||||
出版者 | Pharmaceutical Society of Japan | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 09186158 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1347-5215 | |||||
PubMed番号 | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | PMID | |||||
関連識別子 | 19043206 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1248/bpb.31.2237 | |||||
権利 | ||||||
権利情報 | (c) 2008 Pharmaceutical Society of Japan. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Biological & Pharmaceutical Bulletin, 31(12), pp.2237-2244; 2008 |